Skip to main content
Premium Trial:

Request an Annual Quote

Three RNAi-Related Patent Applications Published by USPTO


Title: RNA Interference-Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid

Number: 20050148530

Filed: April 23, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

The invention "concerns methods and reagents useful in modulating vascular endothelial growth factor (VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D) and/or vascular endothelial growth factor receptor (e.g., VEGFR1, VEGFR2 and/or VEGFr3) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications," the patent application's abstract states. "Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules capable of mediating RNA interference against VEGF and/or VEGFr gene expression and/or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of VEGF and/or VEGFr expression or activity."

Title: Methods of Obtaining Isoform-Specific Expression in Mammalian Cells

Number: 20050148526

Filed: July 22, 2004

PCT Filed: Jan. 22, 2003

Lead Inventor: Malgorzata Anna Kisielow, Friedrich Miescher Institute for Biomedical Research

The patent application covers "a method … for isoform-specific gene expression in a mammalian cell in the absence of other isoforms. The method uses RNAi to achieve the specific expression."

Title: Methods and Compositions for Delivering Polynucleotides

Number: 20050147993

Filed: Oct. 25, 2004

Inventor: Shaharyar Khan, University of Virginia

According to its abstract, the patent application covers "methods and compositions for delivering polynucleotides. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided," the abstract notes.